Putative direct and indirect Wnt targets identified through consistent gene expression changes in APC-mutant intestinal adenomas from humans and mice.
In order to identify new genes with differential expression in early intestinal tumours, we performed mRNA (messenger ribonucleic acid) expression profiling of 16 human and 63 mouse adenomas. All individuals had germline APC mutations to ensure that tumorigenesis was driven by 'second hits' at APC. Using stringent filtering to identify changes consistent between humans and mice, we identified 60 genes up-regulated and 151 down-regulated in tumours. For 22 selected genes--including known Wnt targets--expression differences were confirmed by qRT-PCR (quantitative reverse transcription polymerase chain reaction). Most, but not all, differences were also present in colorectal carcinomas. In situ analysis showed a complex picture. Expression of up-regulated genes in adenomas was usually uniform/diffuse (e.g. ITGA6) or prominent in the tumour core (e.g. LGR5); in normal tissue, these genes were expressed at crypt bases or the transit amplifying zone. Down-regulated genes were often undetectable in adenomas, but in normal tissue were expressed in mesenchyme (e.g. GREM1/2) or differentiated cells towards crypt tops (e.g. SGK1). In silico analysis of TCF4-binding motifs showed that some of our genes were probably direct Wnt targets. Previous studies, mostly focused on human tumours, showed partial overlap with our 'expression signature', but 37 genes were unique to our study, including TACSTD2, SEMA3F, HOXA9 and IER3 (up-regulated), and TAGLN, GREM1, GREM2, MAB21L2 and RARRES2 (down-regulated). Combined analysis of our and published human data identified additional genes differentially expressed in adenomas, including decreased BMPs (bone morphogenetic proteins) and increased BUB1/BUB1B. Several of the newly identified, differentially expressed genes represent potential diagnostic or therapeutic targets for intestinal tumours.
Segditsas
Stefania
S
Molecular and Population Genetics Laboratory, London Research Institute, Cancer Research UK, London WC2A 3PX, UK. stefania.segditsas@cancer.org.uk
Sieber
Oliver
O
Deheragoda
Maesha
M
East
Phil
P
Rowan
Andrew
A
Jeffery
Rosemary
R
Nye
Emma
E
Clark
Susan
S
Spencer-Dene
Bradley
B
Stamp
Gordon
G
Poulsom
Richard
R
Suraweera
Nirosha
N
Silver
Andrew
A
Ilyas
Mohammad
M
Tomlinson
Ian
I
D000236:Adenoma / Q000235:genetics* / Q000378:metabolism; D000818:Animals; D020869:Gene Expression Profiling; D015972:Gene Expression Regulation, Neoplastic / Q000235:genetics; D018390:Gene Targeting; D017491:Genes, APC / Q000502:physiology*; D006801:Humans; D007414:Intestinal Neoplasms / Q000235:genetics* / Q000378:metabolism; D051379:Mice; D009154:Mutation / Q000235:genetics*; D020411:Oligonucleotide Array Sequence Analysis; D051153:Wnt Proteins / Q000502:physiology*
D051153:Wnt Proteins
BMC Cancer. 2006 Mar 18;6:74
16545136
Proc Natl Acad Sci U S A. 2006 Oct 3;103(40):14842-7
17003113
Oncogene. 2005 Apr 28;24(19):3141-53
15735679
Mol Cancer Res. 2007 Dec;5(12):1263-75
18171984
Hepatology. 2003 Mar;37(3):528-33
12601349
J Biol Chem. 2003 Feb 21;278(8):5871-82
12488318
Oncology. 2003;64(4):380-8
12759536
Mol Cells. 2002 Dec 31;14(3):382-7
12521301
Eur J Histochem. 1998;42(2):121-32
9728289
Proc Natl Acad Sci U S A. 2007 Sep 25;104(39):15418-23
17881565
Gastroenterology. 2007 Feb;132(2):628-32
17320548
Int J Cancer. 2008 Jan 15;122(2):298-304
17935134
Genome Biol. 2007;8(7):R131
17615082
Anticancer Res. 2003 Jan-Feb;23(1A):161-5
12680208
Nature. 2008 Jan 3;451(7174):73-5
18172498
Nat Genet. 2008 Jan;40(1):26-8
18084292
Nature. 2007 Oct 25;449(7165):1003-7
17934449
Nat Rev Cancer. 2001 Oct;1(1):55-67
11900252
J Biol Chem. 2008 Jul 11;283(28):19201-10
18487207
Cancer Biol Ther. 2006 Apr;5(4):419-26
16575208
Hum Mol Genet. 2003 Feb 1;12(3):247-55
12554679
Mol Cell Biol. 2008 Apr;28(8):2732-44
18268006
Am J Pathol. 2008 May;172(5):1363-80
18403596
Cancer Res. 2005 Jan 1;65(1):166-76
15665292